About US
We have developed a new omics technology utilising an overlooked class of sugar molecules. It is the World’s only technology that can extract cell state information in a non-invasive manner, and it will be a disruptive force across cell biology, therapeutics and medicine.
The concept of cell states is deeply embedded in cell biology thinking across the entire landscape of cell biology, biopharma therapeutic development, and clinical interventions. The ‘healthy’ cell state as well as the ‘diseased’ cell state are at the core of medicine and basic research. There are many other important cell states that are widely studied, such as individual cell states as part of the cell cycle, the aging cell state, cells that are in a state of cell death progression, stem cell differentiated states, and cells that are in sub types of disease cell states, such as cancer cell states. To date, all of these cell states are investigated and extracted by breaking open the cellular boundary (i.e., invasive) and analysis with cumbersome biochemical techniques, which has profound limitations in the ability to study cell states.
Our patented Cell State Fingerprint Technology (CSF Technology) works by accessing the power of an overlooked sub-set class of cell surface sugar molecules which, combined with information from additional biomarkers, and from the power of our proprietary cell state focused analysis software.
Due to the ubiquitous nature of our biomarkers, the CSF Technology is an all-encompassing platform across
– All species
-All cell types
– All cell states
We are building an ecosystem of integrated technologies that will shape how cell biologists in both industry and academia extract the truth behind cell biology, shape the future of cell biology, and shape the future of medicine and cell therapies for the benefit of knowledge and for patients.
We welcome contact from interested parties in exploring our exciting technology platform further.
Intellectual Property
We have built a suite of intellectual property assets and an integrated product ecosystem to support our platform technologies.
Our central technology platform is supported by four patents, focusing on the cell biology behind our innovations and the use of sophisticated and software analysis. We are also developing further technologies to contribute to innovative ecosystem and portfolio of products.
We are supported by The University of Aberdeen in Scotland and Loughborough University in the Midlands of the UK, where the originating IP was developed.
Product Portfolio
We are currently building our first products that focus on Programmed Cell Death, Aging (senescence) and a range of additional cell biology domains. Our platform technologies can also be used in ‘exploratory mode’ – by which we mean that the technology can be used with whatever the focus of your cell biology/biopharma needs, or alternatively in ‘defined mode’ – effectively through a targeted and guided approach to many of the cell biologists key and common areas of focus.
We are developing the technology in several formats; a high throughput drug discovery platform, a range of exploratory and defined kits, and platform formats for helping cell therapeutic companies (Stem Cell & CAR-T) to optimise yield and efficacy.
Our philosophy
Our guiding philosophy is to bring change to the Life Science Ecosystem for the benefit of science and for the benefit of medicine and therapy. This is central to the three founders’ vision. We know we have a game changing technology that will shape the future of the life sciences. We are aiming at maximising the benefit of this change for the end users and ultimately for the recipients of better therapies. That is why our focus is to maximise the outlook of change through an ecosystem of integrated cell state technologies and an integrated ecosystem of customers and end-users of our technologies.
The team
Dr Paul Burrows, CEO
Founder & Inventor. Paul holds a PhD in biochemistry/cell biology from Imperial College London, and an MBA from Imperial College London.
Dr Patrick Cao, CsO
Founder & Inventor. Patrick holds a degree in natural Sciences from Cambridge University and a PhD from Cambridge University
Dr Dimitris Tampakis, CTo
Founder & Inventor. Dimitris holds a degree from The Democritus University of Thrace, an MSc from Aberdeen University, and a PhD from Loughborough University.
LectomeBio is also joined by Professor Nick Forsythe as the Board representative from Aberdeen University, and Dr Nick Gostick, the Board representative from Loughborough University. We are also joined by an expanding team of advisors including the eminent clinician Professor Mark Vickers and eminent immunologist Professor John Forrester.